financetom
Business
financetom
/
Business
/
Tech distributor ScanSource's Q4 sales, profit beat estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tech distributor ScanSource's Q4 sales, profit beat estimates
Aug 21, 2025 5:56 AM

Overview

* ScanSource ( SCSC ) Q4 net sales rise 8.9%, beating analyst expectations, per LSEG data

* Adjusted EPS for Q4 beats consensus, rising to $1.02, per LSEG data

* Adjusted EBITDA for Q4 increases 13%, surpassing estimates, per LSEG data

Outlook

* ScanSource ( SCSC ) sees FY26 net sales between $3.1 bln and $3.3 bln

* Company expects FY26 adjusted EBITDA of $150 mln to $160 mln

* ScanSource ( SCSC ) anticipates FY26 free cash flow of at least $80 mln

Result Drivers

* RECURRING REVENUE - Recurring revenue increased 30% year-over-year, driven by acquisitions

* NORTH AMERICA GROWTH - Specialty Technology Solutions sales rose 9.2%, fueled by broad-based growth in North America

* PRODUCT AND SERVICE SALES - Net sales for products and services grew 8.1% year-over-year

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Sales Beat $812.89 $776.90

mln mln (3

Analysts

)

Q4 Beat $1.02 $0.92 (3

Adjusted Analysts

EPS )

Q4 Beat $23.32 $22.10

Adjusted mln mln (2

Net Analysts

Income )

Q4 Beat $38.64 $36.60

Adjusted mln mln (3

EBITDA Analysts

)

Q4 Gross $105.10

Profit mln

Q4 $26.79

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the computer hardware peer group is "buy"

* Wall Street's median 12-month price target for Scansource Inc ( SCSC ) is $54.00, about 21.2% above its August 20 closing price of $42.53

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
KKR Completes Acquisition of OSTTRA From S&P Global and CME Group
KKR Completes Acquisition of OSTTRA From S&P Global and CME Group
Oct 10, 2025
NEW YORK--(BUSINESS WIRE)-- KKR, a leading global investment firm, today announced that investment funds managed by KKR have completed the acquisition of OSTTRA, a leading provider of post-trade solutions for the global OTC market, from S&P Global and CME Group. The terms of the deal for OSTTRA equaled total enterprise value at $3.1 billion. Established in 2021 as a joint...
S&P Global and CME Group Complete Sale of OSTTRA to KKR
S&P Global and CME Group Complete Sale of OSTTRA to KKR
Oct 10, 2025
NEW YORK, Oct. 10, 2025 /PRNewswire/ -- S&P Global ( SPGI ) and CME Group today announced that they have completed the sale of OSTTRA to KKR, a leading global investment firm. The terms of the deal for OSTTRA equaled total enterprise value at $3.1 billion, which will be divided evenly between S&P Global ( SPGI ) and CME Group...
Serve Robotics Announces $100 Million Registered Direct Offering of Common Stock
Serve Robotics Announces $100 Million Registered Direct Offering of Common Stock
Oct 10, 2025
SAN FRANCISCO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Serve Robotics Inc. ( SERV ) (Serve or the Company) , a leading autonomous sidewalk delivery company, announced today that the Company has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 6,250,000 shares of common stock, pursuant to a registered direct offering, expected to result...
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
Oct 10, 2025
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further strengthens BMS’s industry-leading cell therapy portfolio, expanding CAR T-cell access to more patients in the future PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bristol Myers Squibb ( BMY ) and Orbital Therapeutics (“Orbital”) today announced a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved